NASDAQ · IINN
Inspira Technologies OXY B.H.N. Ltd.
$1.05-$0.01 (-0.94%)
Inspira Technologies OXY B.H.N. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
Loading market information…
NASDAQ · PAVM · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
PAVmed Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.07% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
PAVmed Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.63. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow PAVmed Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 14, 2025 |
| -$2.10+75.89% vs estimate |
| $8.00K-20.0% vs estimate |
| Q4 2024 | Mar 24, 2025 | -$1.80+45.45% vs estimate | $10.00K-50.0% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | $16.22+719.19% vs estimate | $996.00K-8.9% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.05-$0.01 (-0.94%)
Inspira Technologies OXY B.H.N. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$3.61+$0.24 (+7.12%)
HeartSciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.2% below the high.
$11.05-$1.21 (-9.87%)
Burning Rock Biotech Limited’s quoted price sits in the lower half of its reported 52-week range, 73.51% below the high.
$1.74-$0.01 (-0.57%)
Biomerica, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.82% below the high.
$2.64-$0.34 (-11.41%)
Advanced Biomed Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 89.1% below the high.
$0.28-$0.02 (-5.73%)
Pheton Holdings Ltd Class A Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 99.12% below the high.
$1.36+$0.06 (+4.62%)
Aptevo Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.22% below the high.
$2.29+$0.03 (+1.33%)
Tenon Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.97% below the high.
